REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The CONTAIN phase III trial evaluated the benzodiazepine derivative clobazam in patients with Lennox-Gastaut syndrome (LGS) (Ng et al. Neurology 2011;77:1473-1481). A total of 238 patients aged 2-60 years (mean 12.4 years) were randomized to one of three doses of clobazam (0.25, 0.5, 1.0 mg/kg/day) or placebo.